EMD-25209
Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab
EMD-25209
Single-particle4.3 Å
Deposition: 27/10/2021Map released: 08/12/2021
Last modified: 04/06/2025
Sample Organism:
Severe acute respiratory syndrome coronavirus 2,
Homo sapiens
Sample: SARS-CoV-2_Hexapro in complex with neutralizing antibody C1C-A3 Fab from human patient
Fitted models: 7sn2
Deposition Authors: Pan J
,
Abraham J
Sample: SARS-CoV-2_Hexapro in complex with neutralizing antibody C1C-A3 Fab from human patient
Fitted models: 7sn2
Deposition Authors: Pan J
,
Abraham J
Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
Nabel KG,
Clark SA ,
Shankar S ,
Pan J ,
Clark LE ,
Yang P ,
Coscia A ,
McKay LGA ,
Varnum HH,
Brusic V,
Tolan NV ,
Zhou G,
Desjardins M ,
Turbett SE ,
Kanjilal S ,
Sherman AC ,
Dighe A,
LaRocque RC ,
Ryan ET,
Tylek C,
Cohen-Solal JF ,
Darcy AT,
Tavella D ,
Clabbers A ,
Fan Y,
Griffiths A ,
Correia IR ,
Seagal J ,
Baden LR,
Charles RC,
Abraham J
(2022) Science , 375 , eabl6251 - eabl6251
,
Shankar S ,
Pan J ,
Clark LE ,
Yang P ,
Coscia A ,
McKay LGA ,
Varnum HH,
Brusic V,
Tolan NV ,
Zhou G,
Desjardins M ,
Turbett SE ,
Kanjilal S ,
Sherman AC ,
Dighe A,
LaRocque RC ,
Ryan ET,
Tylek C,
Cohen-Solal JF ,
Darcy AT,
Tavella D ,
Clabbers A ,
Fan Y,
Griffiths A ,
Correia IR ,
Seagal J ,
Baden LR,
Charles RC,
Abraham J
(2022) Science , 375 , eabl6251 - eabl6251
Grant Support:
- Other private: no grant number (United States)